Active Not RecruitingPhase 1NCT00264602

Real-Time Image Guided Lymphatic Mapping and Nodal Targeting in Lung Cancer

The primary purpose of this study is to determine if we can identify the first lymph node that drains from the tumor, and thus would be the most likely site for metastatic disease, and remove it for analysis to improve the ability to detect tumor in this node and to remove this additional site that potentially contains tumor cells.

Checked against the public recordLast updated Nov 10, 2025 · Source: ClinicalTrials.gov

StatusActive Not Recruiting
PhasePhase 1
U.S. locations4
SponsorDana-Farber Cancer Institute
01
Study overview

What this study is about

Purpose
Diagnostic
Study type
Interventional
Phase
Phase 1
Sponsor
Dana-Farber Cancer Institute
Interventions being studied
Drug: Near Infrared Imaging
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

03
Public criteria

Who may be able to participate

Inclusion Criteria: * Suspected or histologically documented new non-small cell carcinoma that have agreed to undergo a thoracotomy for segmentectomy, lobectomy, bilobectomy or pneumonectomy as recommended by their thoracic surgeon for treatment * Surgically resectable lung cancer * N2 lymph nodes negative on PET scan or mediastinoscopy * Age \> or equal to 18 years of age * Men, women of non-child bearing age or women with a negative pregnancy test Exclusion Criteria: * Patient does not want to undergo subsequent surgical resection * Medical condition such as uncontrolled infection or cardiac disease that, i the opinion of the treating surgeon, makes resection unreasonably hazardous for the patient. * T4 or N2 disease * Pre-operative spirometry that suggests they cannot undergo resection of their primary tumor by segmentectomy, lobectomy, bilobectomy, or pneumonectomy * Iodide or seafood allergy * Pregnant or lactating women

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Massachusetts General HospitalBoston, Massachusetts
  • Beth Israel Deaconess Medical CenterBoston, Massachusetts
  • Brigham and Women's HospitalBoston, Massachusetts
  • Dana-Farber Cancer InstituteBoston, Massachusetts

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Nov 10, 2025. Always confirm current availability with the study team.

View original record ↗